Meridian Bioscience Reports Second Quarter 2019 Operating Results, Suspends Quarterly Cash Dividend, and Provides Fiscal 2019 Guidance for Pending Acquisition

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. HOOD
8. DFTX
9. MU
10. IBM

Go back to Meridian Bioscience Reports Second Quarter 2019 Operating Results, Suspends Quarterly Cash Dividend, and Provides Fiscal 2019 Guidance for Pending Acquisition

Piper Jaffray Upgrades Meridian Biosciences (VIVO) to Neutral

May 1, 2019 2:36 AM EDT

Piper Jaffray analyst William Quirk upgraded Meridian Biosciences (NASDAQ: VIVO) from Underweight to Neutral with a price target of $11.00 (from $15.00).

For an analyst ratings summary and ratings history on Meridian Biosciences click here. For more ratings news on Meridian Biosciences click here.

Shares of Meridian Biosciences closed at $11.51 yesterday.

... More